Summary
Background Recent research demonstrates that α-synuclein seed amplification assays (αSyn-SAA) accurately differentiate Parkinson’s disease (PD) patients from healthy controls (HC). We used the well-characterized, multicenter Parkinson’s Progression Markers Initiative (PPMI) cohort to further assess the diagnostic performance of αSyn-SAA and to examine whether the assay identifies heterogeneity among patients and enables early identification in at-risk groups.
Methods αSyn-SAA analysis of cerebrospinal fluid (CSF) was performed using previously described methods. We assessed sensitivity and specificity in PD and HC, including subgroups based on genetic and clinical features. We determined the frequency of positive αSyn-SAA results in prodromal participants (REM sleep behavior disorder and hyposmia) and non-manifesting carriers (NMCs) of genetic variants associated with PD and compared αSyn-SAA to clinical measures and other biomarkers.
Findings 1,123 participants were included: 545 PD, 163 HCs, 54 participants with scans without evidence of dopaminergic deficit (SWEDDs), 51 prodromal participants, and 310 NMCs. Sensitivity and specificity for PD versus HC were 88% and 96%, respectively. Sensitivity in sporadic PD with the typical olfactory deficit was 99%. The proportion of positive αSyn-SAA was lower in subgroups including LRRK2 PD (68%) and sporadic PD patients without olfactory deficit (78%). Participants with LRRK2 variant and normal olfaction had an even lower αSyn-SAA positivity rate (35%). Among prodromal and at-risk groups, 86% of RBD and hyposmic cases had positive αSyn-SAA. 8% of NMC (either LRRK2 or GBA) were positive.
Interpretation This study represents the largest analysis of αSyn-SAA for biochemical diagnosis of PD. Our results demonstrate that the assay classifies PD patients with high sensitivity and specificity, provides information about molecular heterogeneity, and detects prodromal individuals prior to diagnosis. These findings suggest a crucial role for αSyn-SAA in therapeutic development, both to identify pathologically defined subgroups of PD patients and to establish biomarker-defined at-risk cohorts.
Funding PPMI – a public-private partnership – is funded by the Michael J. Fox Foundation for Parkinson’s Research and funding partners, including: PPMI is supported by a consortium of private and philanthropic parnters: Abbvie, AcureX, Aligning Science Across Parkinson’s, Amathus Therapeutics, Avid Radiopharmaceuticals, Bial Biotech, Biohaven, Biogen, BioLegend, Bristol-Myers Squibb, Calico Labs, Celgene, Cerevel, Coave, DaCapo Brainscience, 4D Pharma, Denali, Edmond J. Safra Foundation, Eli Lilly, GE Healthcare, Genentech, GlaxoSmithKline, Golub Capital, Insitro, Janssen Neuroscience, Lundbeck, Merck, Meso Scale Discovery, Neurocrine Biosciences, Prevail Therapeutics, Roche, Sanofi Genzyme, Servier, Takeda, Teva, UCB, VanquaBio, Verily, Voyager Therapeutics, and Yumanity.
Evidence before the study We searched PubMed with the terms Parkinson’s disease (PD), prodromal, Non-manifest carriers, GBA, LRRK2 and real-me quaking-induced conversion (RT-QuIC), protein misfolding cyclic amplification (PMCA), and seed amplification assay (SAA) for articles published in English on or before Oct 25, 2022, in any field. This is a large and rapidly growing literature, and a number of studies were identified, including case-series of PD patients with and without genetic variants, individuals with isolated REM sleep behavior disorder (RBD), and a small number of studies of non-manifesting carriers of genetic variants (4) associated with PD.
Added value of the study To our knowledge, this is the largest report of comparative data from a cohort of PD patients, healthy controls, individuals with clinical syndromes prodromal to PD (hyposmia and RBD), and non-manifest carriers of LRRK2 G2019S and GBA N370S mutations. The strengths of our data include a large sample size, robust clinical data set, a high percentage of DAT scans completed, and the ability to compare non-manifest carriers to similar aged healthy controls, which allows for inter-group comparisons and sub-group analysis. The key novel findings in this study include: 1) marked variability in rates of positive αSyn-SAA results particularly among LRRK2 variant carriers depending on olfactory performance and sex; 2) αSyn-SAA positivity in prodromal and NMCs without dopaminergic imaging abnormalities in a substantial number of cases, while the converse is less common, indicating that αSyn-SAA may be a very early indicator of synucleinopathy. We also confirmed the high diagnostic accuracy of αSyn-SAA for sporadic PD vs. HC and that αSyn-SAA is negative in the vast majority of NMC, suggesting that the presence of synuclein aggregates in CSF is not a life-long trait but rather acquired at some point relatively close to disease onset.
Implications of all available evidence Our results demonstrate that the assay classifies PD patients with high sensitivity and specificity, provides information about molecular heterogeneity, and detects prodromal individuals prior to diagnosis. These findings suggest a crucial role for αSyn-SAA in therapeutic development, both to identify pathologically defined subgroups of PD patients and to establish biomarker-defined at-risk cohorts.
Competing Interest Statement
AuthorInterests (Examples of financial conflicts include employment, consultancies, stock ownership, honoraria, paid expert testimony, patents or patent applications, and travel grants, all within 3 years of beginning the work submitted. If there are no conflicts of interest, authors should state that none exist) Andrew SiderowfEmployment: None Consultancies: Merck, Parkinson Study Group Stock ownership: None Honoraria: Bial Paid expert testimony: None Patents or patent applications: None Travel grants: None Luis Concha-MarambioEmployment: Amprion Consultancies: None Stock ownership: Amprion Employee stock options Honoraria: None Paid expert testimony: None Patents or patent applications: US 20210277076A1, US 20210311077A1, US 20190353669A1 US 20210223268A1 Travel grants: None David-Erick LafontantEmployment: None Consultancies: None Stock ownership: None Honoraria: None Paid expert testimony: None Patents or patent applications: None Travel grants: None Carly M. FarrisEmployment: Amprion Consultancies: None Stock ownership: Amprion Employee stock options Honoraria: None Paid expert testimony: None Patents or patent applications: US 20210277076A1, US 20210311077A1 Travel grants: None Yihua MaEmployment: Amprion Consultancies: None Stock ownership: Amprion Employee stock options Honoraria: None Paid expert testimony: None Patents or patent applications: US 20210277076A1 Travel grants: None Paula A. UreniaEmployment: Amprion Consultancies: None Stock ownership: Amprion Employee stock options Honoraria: None Paid expert testimony: None Patents or patent applications: None Travel grants: None Hieu NguyenEmployment: Amprion Consultancies: None Stock ownership: Amprion Employee stock options Honoraria: None Paid expert testimony: None Patents or patent applications: None Travel grants: None Roy N. AlcalayEmployment: None Consultancies: Janssen (2019 received in 2020), Sanofi (2022), Ono Therapeutics (2021), Avrobio (2021), Takeda (2022), Gain Therapeutics (2022), Merck (2021), GSK (2021), Caraway (2021) Stock ownership: None Honoraria: None Paid expert testimony: None Patents or patent applications: None Travel grants: None Lana M. ChahineEmployment: None Consultancies: None Stock ownership: None Honoraria: Royalties from Elsevier and Wolters Kluwel Paid expert testimony: None Patents or patent applications: None Travel grants: None Tatiana ForoudEmployment: None Consultancies: None Stock ownership: None Honoraria: None Paid expert testimony: None Patents or patent applications: None Travel grants: Michael J. Fox Foundation reimbursement for travel expenses Douglas GalaskoEmployment: None Consultancies: None Stock ownership: None Honoraria: None Paid expert testimony: None Patents or patent applications: None Travel grants: None Karl KieburtzEmployment: None Consultancies: None Stock ownership: None Honoraria: None Paid expert testimony: None Patents or patent applications: None Travel grants: None Kalpana MerchantEmployment: None Consultancies: Michael J. Fox Foundation, AcuRx, Caraway, Cerebral Therapeutics, NRG Therapeutics (SAB), Nurabio, Retromer Therapeutics (Director on the board, Pd part time CSO), Schrodinger, Sinopia Biosciences (SAB) and Vanqua Biosciences (SAB) Stock ownership: Cognition Therapeutics, Eli Lilly (retiree stock holder), Envisagenics, Retromer Therapeutics Honoraria: University of Utah lectures Paid expert testimony: None Patents or patent applications: Retromer Therapeutics planned patent Travel grants: University of Utah Brit MollenhauerEmployment: None Consultancies: Roche, Biogen, Michael J. Fox Foundation Stock ownership: None Honoraria: Abbvie Paid expert testimony: None Patents or patent applications: None Travel grants: Abbvie Kathleen L. PostonEmployment: None Consultancies: Curasen Stock Ownership: Scientific Advisory Board for Curasen, Scientific Advisory Board for Amprion Honoraria: Honoraria from invited scientific presentations to universities and professional societies not exceeding $5000/yr Paid expert testimony: None Patents or patent applications: Application No. 17/314,979 filed on May 19, 2021 and Application No. 63/377,293 filed on September 27, 2022 Travel grants: None John SeibylEmployment: None Consultancies: Invicro, Biogen, Abbvie Stock ownership: RealmIDX, MNI Holdings, LikeMinds Honoraria: None Paid expert testimony: None Patents or patent applications: None Travel grants: None Tanya SimuniEmployment: None Consultancies: 4D Pharma, Acadia, AcureX, AskBio, Amneal, Blue Rock Therapeutics, Caraway, Critical Path for Parkinson's Consortium (CPP), Denali, MJFF, Neuroderm, Roche, Sanofi, Sinopia, Sunovion, Takeda, UCB, Vanqua Bio and Voyager Stock ownership: None Honoraria: None Paid expert testimony: None Patents or patent applications: None Travel grants: None Caroline M. TannerEmployment: None Consultancies: CNS Ratings, Australian Parkinsons Mission, Biogen, Evidera, Receives consulting fees from Cadent (DSMB), Adamas (Steering Committee), Biogen (via Parkinson Study Group) Steering Committee, Kyowa Kirin (Advisory Board), Lundbeck (Advisory Board), Jazz/Cavion (Steering Committee), Acorda (Advisory Board) Stock ownership: None Honoraria: None Paid expert testimony: None Patents or patent applications: None Travel grants: None Daniel WeintraubEmployment: Receives salary support from MJFF for serving on Executive Steering Committee for PPMI Consultancies: None Stock ownership: None Honoraria: None Paid expert testimony: None Patents or patent applications: None Travel grants: None Aleksandar VidenovicEmployment: None Consultancies: CoA Therapeutics, XW Pharma, Biogen Stock ownership: None Honoraria: None Paid expert testimony: None Patents or patent applications: None Travel grants: None Seung Ho ChoiEmployment: None Consultancies: None Stock ownership: None Honoraria: None Paid expert testimony: None Patents or patent applications: None Travel grants: None Ryan KurthEmployment: None Consultancies: None Stock ownership: None Honoraria: None Paid expert testimony: None Patents or patent applications: None Travel grants: None Chelsea Caspell-GarciaEmployment: None Consultancies: None Stock ownership: None Honoraria: None Paid expert testimony: None Patents or patent applications: None Travel grants: None Christopher S. CoffeyEmployment: None Consultancies: None Stock ownership: None Honoraria: None Paid expert testimony: None Patents or patent applications: None Travel grants: None Mark FrasierEmployment: Michael J. Fox Foundation Consultancies: None Stock ownership: None Honoraria: None Paid expert testimony: None Patents or patent applications: None Travel grants: None Luis M. A. OliveiraEmployment: Michael J. Fox Foundation Consultancies: None Stock ownership: None Honoraria: None Paid expert testimony: None Patents or patent applications: None Travel grants: None Samantha J. HuttenEmployment: None Consultancies: None Stock ownership: None Honoraria: None Paid expert testimony: None Patents or patent applications: None Travel grants: None Todd ShererEmployment: Michael J. Fox Foundation Consultancies: None Stock ownership: None Honoraria: None Paid expert testimony: None Patents or patent applications: None Travel grants: None Kenneth MarekEmployment: None Consultancies: Invicro, MJFF, Roche, Calico, Coave, Neuron23, Orbimed, Neuroderm, Sanofi, Takeda, Merck, Lilly, Inhibikase, Neuramedy Stock ownership: None Honoraria: None Paid expert testimony: None Patents or patent applications: None Travel grants: None Claudio SotoEmployment: Founder, Chief Scientific Officer, Consultant, shareholder and member of the Board of Directors of Amprion Inc. Consultancies: Amprion Stock ownership: Amprion Honoraria: Will receive royalties for the sale of SAA from Amprion Paid expert testimony: None Patents or patent applications: Several patents awarded and amplified in conjunction with Amprion for the SAA assay Travel grants: None
Clinical Protocols
https://www.ppmi-info.org/study-design/research-documents-and-sops
Funding Statement
PPMI, a public-private partnership, is funded by the Michael J. Fox Foundation for Parkinson's Research funding partners 4D Pharma, Abbvie, Acurex Therapeutics, Allergan, Amathus Therapeutics, ASAP, Avid Radiopharmaceuticals, Bial Biotech, Biogen, BioLegend, Bristol-Myers Squibb, BlueRock Therapeutics, Calico, Celgene, Dacapo Brain Science, Denali, The Edmond J. Safra Foundaiton, GE Healthcare, Genentech, GlaxoSmithKline, Golub Capital, Handl Therapeutics, Insitro, Janssen Neuroscience, Lilly, Lundbeck, Merck, Meso Scale Discovery, Neurocrine Biosciences, Pfizer, Piramal, Prevail, Roche, Sanofi Genzyme, Servier, Takeda, Teva, UCB, Verily, and Voyager Therapeutics
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study used openly available data from the PPMI study - https://www.ppmi-info.org/access-data-specimens/download-data
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵†† Refer to appendix for full list of PPMI investigators
Data Availability
All data produced are available online at https://www.ppmi-info.org/access-data-specimens/download-data
https://www.ppmi-info.org/access-data-specimens/download-data
